SCHEMBL3655338

SCHEMBL3655338

NC(=O)C1=Cc2cnccc2NC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT3 Q9NTG7 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
F7 P08709 1/20 0.36
F3 P13726 1/20 0.36
SARM1 Q6SZW1 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
SIRT6 Q8N6T7 1/20 0.36
SIRT1 Q96EB6 1/20 0.36
SIRT5 Q9NXA8 1/20 0.36
SIRT4 Q9Y6E7 1/20 0.36
CDK8 P49336 10/20 0.33
CHEK1 O14757 1/20 0.33
AURKA O14965 1/20 0.33
DAPK3 O43293 1/20 0.33
PRKD3 O94806 1/20 0.33
MAP4K4 O95819 1/20 0.33
PAK4 O96013 1/20 0.33
ABL1 P00519 1/20 0.33
RET P07949 1/20 0.33
PIM1 P11309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29623343 1.00 SIRT3 (0.38) SIRT3TDP1F7F3SARM1
SCHEMBL30539758 0.87 SIRT3 (0.38) SIRT3TDP1F7F3SARM1
SCHEMBL8366169 0.85 KDM4C (0.36) TDP1TSHRKDM4EMKNK1MKNK2
SCHEMBL30440354 0.85 KDM4C (0.36) TDP1TSHRKDM4EMKNK1MKNK2
SCHEMBL35211554 0.80
SCHEMBL715561 0.78 HSD17B10 (0.33) TDP1AURKATSHRKDM4EALDH1A1
Hydrochloric Acid SCHEMBL6204990 0.77 HSD17B3 (0.33) TDP1AURKATSHRMAPTL3MBTL1
SCHEMBL2877013 0.74 PRKCI (0.40) CDK8CHEK1DAPK3PRKD3MAP4K4
SCHEMBL30818429 0.73 SIRT3 (0.40) SIRT3TDP1F7F3SARM1
SCHEMBL27791683 0.72 KDM4C (0.37) TDP1KDM4EMEN1KDM6BKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023056951-A1 ARYL-SUBSTITUTED HETEROCYCLIC COMPOUND 杭州德睿智药科技有限公司 2023-04-13 WO disclosed
CN-108137587-B Method for preparing and recovering amide compound 拜耳制药股份公司 2020-10-23 CN disclosed
CN-110511219-A The dihydronaphthridine class compound and application thereof that phenyl replaces GUANGDONG HEC PHARMACEUTICAL 2019-11-29 CN disclosed
CN-110022871-A Combination comprising sGC stimulators and mineralocorticoid receptor antagonists 拜耳制药股份公司 2019-07-16 CN disclosed
CN-109890379-A Combination comprising an sGC activator and a mineralocorticoid receptor antagonist 拜耳制药股份公司 2019-06-14 CN disclosed
CN-108473488-A The preparation method and its usage of the metabolin of (4S)-and (4R) -4- (4- cyano -2- methoxyphenyls) -5- ethyoxyl -2,8- dimethyl -1,4- dihydro -1,6- naphthyridines -3- formamides 拜耳制药股份公司 2018-08-31 CN disclosed
CN-108137587-A Method for producing (4S) -4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2, 8-dimethyl-1, 4-dihydro-1, 6-naphthyridine-3-carboxamide by means of electrochemical methods and for recovering (4S) -4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2, 8-dimethyl-1, 4-dihydro-1, 6-naphthyridine-3-carboxamide 拜耳制药股份公司 2018-06-08 CN disclosed
CN-107849043-A For preparing the method for the formamide of 1,6 naphthyridines of (4S) 4 (methoxyphenyl of 4 cyano group 2) 5 ethyoxyl, 2,8 dimethyl, 1,4 dihydro 3 and its for the purifying as pharmaceutically active substance 拜耳制药股份公司 2018-03-27 CN disclosed
EP-2201010-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2010-06-30 EP disclosed
WO-2009036412-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-03-19 WO disclosed